- Wheeler Bio has launched a redesigned website to showcase its expanded biologics development and manufacturing capabilities, including services from cell line development through cGMP drug substance and drug product manufacturing.
- The updated site highlights the company’s AI/ML-enabled ModularCMC™ platform and provides expanded information on its facilities, service offerings, and partner network.
Wheeler Bio has launched a redesigned website that reflects the company’s expanded capabilities as a contract development and manufacturing organization (CDMO) for antibody-based therapeutics. The new site is designed to provide biotechnology companies with a clearer view of the company’s development and manufacturing services, facilities, scientific expertise, and partner network.
According to Wheeler Bio, the website highlights its evolution into an integrated CDMO supporting biologics programs from cell line development through cGMP drug substance and drug product manufacturing. The company said the platform also outlines its approach to client engagement, which combines scientific expertise with project management and communication support.
A central feature of the updated website is Wheeler Bio’s AI/ML-enabled ModularCMC™ platform. The company described the platform as a structured, phase-appropriate development approach that incorporates standardized work packages, Quality-by-Design principles, and AI/ML-informed process development strategies. Wheeler Bio said the platform is designed to support antibody-based therapeutics, including monoclonal antibodies, multispecific antibodies, Fc-fusion proteins, and antibody-drug conjugates.
“As Wheeler Bio continues to grow, it was important that our digital presence reflect the full breadth of capabilities, expertise, and capacity we bring to our clients.”
Sheli Streck, Chief Commercial Officer at Wheeler Bio
The redesigned website includes enhanced navigation, expanded technical content, updated service descriptions, and additional resources intended to help biotechnology companies assess development and manufacturing options. The company said the website reflects its broader biologics development and contract manufacturing capabilities as well as its approach to supporting clients from discovery through cGMP manufacturing.
